When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
SGEN - Seattle Genetics ADC combo shows positive effect in advanced bladder cancer
Seagen Inc.
Seattle Genetics (NASDAQ:SGEN) and collaboration partner Astellas Pharma (OTCPK:ALPMF) announce updated results from an open-label Phase 1b/2 clinical trial evaluating the combination of antibody-drug conjugate (ADC) PADCEV (enfortumab vedotin-ejfv) and Merck's Keytruda (pembrolizumab) in previously untreated patients with locally advanced or metastatic urothelial cancer who are ineligible for treatment with cisplatin-based chemo. The data will be presented at the ASCO GU Cancers Symposium in San Francisco.
More news on: Seattle Genetics, Inc., Astellas Pharma Inc., Astellas Pharma Inc., Healthcare stocks news,